Elevated high-sensitivity C-reactive protein levels predict poor outcomes among patients with acute cardioembolic stroke

Wang, Shumin; Song, Xingyou; Wang, Yajing; Gao, Yuan; Wu, Jialing

doi:10.21037/apm-20-1927

Cited by 4 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the ROC curves, we found that serum sLOX‐1 and Lp‐PLA2 levels have high diagnostic values for predicting long‐term functional outcomes after ACI, and the combination of the serum sLOX‐1 and Lp‐PLA2 can significantly improve the specificity of prediction without scarifying the sensitivity. Serum level of hs‐CRP is another biomarker that has been studied for ACI (Wang et al, 2021 ). However, combining hs‐CRP with sLOX‐1 improved the sensitivity at the expense of specificity, whereas combining hs‐CRP with Lp‐PLA2 did not yield any improvement.…”

Section: Discussionmentioning

confidence: 99%

Serum levels of sLOX‐1 and Lp‐PLA2 can predict the prognosis of acute cerebral infarction with a high specificity

Yan

Cao

Zhou

et al. 2022

Physiological Reports

View full text Add to dashboard Cite

Soluble lectin‐like oxidized low‐density lipoprotein receptor‐1 (sLOX‐1) and lipoprotein‐associated phospholipase A2 (Lp‐PLA2) plays an important role in acute cerebral infarction (ACI), whereas its clinical value in predicting the prognosis is unclear. Thus, this study aimed to explore this issue. A total of 127 ACI patients were included in this prospective observational study. The concentrations of sLOX‐1 and Lp‐PLA2 in serum were measured and their relationship with a poor prognosis 90 days after the onset of ACI was analyzed. We found that patients with poor prognosis had higher mean serum levels of sLOX‐1 and Lp‐PLA2. The level of sLOX‐1 and Lp‐PLA2 could predict the functional outcome of ACI. At the optimal cut off value of sLOX‐1 level (1257.92 ng/ml), the sensitivity and specificity for the poor functional outcome were 0.69 and 0.753, respectively, and the area under ROC curve (AUC) was 0.727. Similarly, the optimal value for Lp‐PLA2 level was 160.9 ng/ml, at which the sensitivity and specificity were 0.643 and 0.835, respectively; and the AUC was 0.758. When the two biomarkers were used in combination, the AUC was 0.855, and the sensitivity and specificity were 0.643 and 0.976, respectively, indicating a significant improvement of the diagnostic specificity. The level of sLOX‐1 or Lp‐PLA2 could thus serve as useful biomarkers to predict the functional outcome of ACI. Combined use of both indicators is better than the use of either single indicator, and provides the highest specificity in predicting poor prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum levels of sLOX‐1 and Lp‐PLA2 can predict the prognosis of acute cerebral infarction with a high specificity

Yan

Cao

Zhou

et al. 2022

Physiological Reports

View full text Add to dashboard Cite

show abstract

“…For instance, a randomized controlled study reported that high-dose statins could reduce the level of inflammatory indicators and improve the outcome of ischemic stroke [29]. Elevated high-sensitivity C-reactive protein and inflammatory indicators also predicted poor outcome of stroke [30,31]. However, the effect of inflammatory indicators on BADrelated stroke was unknown.…”

Section: Introductionmentioning

confidence: 99%

Study protocol of Branch Atheromatous Disease-related stroke (BAD-study): a multicenter prospective cohort study

Fan

et al. 2022

BMC Neurol

View full text Add to dashboard Cite

Background As a meaningful subtype of ischemic stroke in Asians, Branch atheromatous disease (BAD)-related stroke is associated with high early neurological deterioration (END) and disability, but is understudied and without recommended therapy. The mechanism of END still remains unclear. Branch atheromatous disease-related stroke study (BAD-study) therefore aims to investigate demographic, clinical and radiological features, and prognosis of BAD-related stroke in Chinese patients. Methods/design BAD-study is a nationwide, multicenter, consecutive, prospective, observational cohort study enrolling patients aged 18–80 years with BAD-related stroke within 72 h after symptom onset. Initial clinical data, laboratory tests, and imaging data are collected via structured case report form, and follow-ups will be performed at 7 days, 30 days, 90 days, 6 months and 12 months after enrollment. The primary outcome is the score on modified Rankin Scale at 90-day follow-up with single-blinded assessment. Secondary outcomes include END within 7 days, and National institute of health stroke scale score, Barthel index, cerebrovascular events, major bleeding complications, and all-cause mortality during 90-day follow-up. Characteristics of penetrating and parent artery will be assessed by high-resolution magnetic resonance imaging combined with other imaging techniques. Discussion BAD-study can provide demographic, clinical, radiological, and prognostic characteristics of BAD-related stroke, and thereby potentially figure out the vascular mechanism of early neurological deterioration and optimize therapy strategy with the aid of advanced imaging technique. Baseline data and evidence will also be generated for randomized controlled trials on BAD-related stroke in the future.

show abstract

Research Progress on the Role of Serum hs-CRP and CysC Levels in Ischemic Stroke

高

2024

JCPM

View full text Add to dashboard Cite

Elevated high-sensitivity C-reactive protein levels predict poor outcomes among patients with acute cardioembolic stroke

Cited by 4 publications

References 40 publications

Serum levels of sLOX‐1 and Lp‐PLA2 can predict the prognosis of acute cerebral infarction with a high specificity

Serum levels of sLOX‐1 and Lp‐PLA2 can predict the prognosis of acute cerebral infarction with a high specificity

Study protocol of Branch Atheromatous Disease-related stroke (BAD-study): a multicenter prospective cohort study

Research Progress on the Role of Serum hs-CRP and CysC Levels in Ischemic Stroke

Contact Info

Product

Resources

About